1Liaw Y F, Leung N, Guan R, et al. Asian- Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003,18(3): 239-245.
2Fung S K, Lok A S. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection. Hepatology, 2004,40 (4): 790-792.
3Janssen H L A, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet,2005,365(9454): 123-129.
4Santantonio T, Mazola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol,2000,32(2): 300-306.
5Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology,2000,31(1): 207-210.
6Liaw YF, Sung JJY, Chow WE, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med,2004,351 (12):1521-1531.
7Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis,2003,36(6): 687-696.
8Liaw YF, Chien RN, Ye CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology,1999,30(2): 567-572.
9Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of longterm lamivudine monotherapy in patients with hepatitis B e antigennegative chronic hepatitis B. Hepatology, 2000,32(4 Pt 1 ): 847-851.
10Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology, 2000,31 (6):1318-1326.
10Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931